Scisparc Ltd Cash Flow Conversion Efficiency
Scisparc Ltd cash flow conversion efficiency. Based on the latest financial reports, Scisparc Ltd (SPRC) has a cash flow conversion efficiency ratio of -0.442x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.28 Million) by net assets ($5.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Scisparc Ltd (2006–2025)
Cash flow conversion efficiency of Scisparc Ltd from 2006 to 2025. This chart illustrates how Scisparc Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Scisparc Ltd for real-time trading data and today's change.
Scisparc Ltd Cash Flow Conversion Ratio Explained
Scisparc Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Scisparc Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scisparc Ltd ranked by their cash flow conversion efficiency. Also see how much is Scisparc Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Phoenix Motor Inc. Common Stock
NASDAQ:PEV
|
-0.277x |
|
Eratex Djaja Tbk
JK:ERTX
|
0.189x |
|
Modular Medical Inc
NASDAQ:MODD
|
-1.217x |
|
Check-Cap Ltd
F:7CC
|
-1.030x |
|
ERG S.A.
WAR:ERG
|
0.048x |
|
Af Legal Group Ltd
AU:AFL
|
-0.015x |
|
Proactis SA
PA:PROAC
|
5.290x |
|
Kko International SA
PA:ALKKO
|
-0.098x |
Annual Cash Flow Conversion Efficiency for Scisparc Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Scisparc Ltd from 2006 to 2025. Review SPRC financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.15 Million | $-4.14 Million | -0.804x | -40.77% |
| 2024-12-31 | $8.94 Million | $-5.10 Million | -0.571x | +7.02% |
| 2023-12-31 | $9.59 Million | $-5.89 Million | -0.614x | +49.98% |
| 2022-12-31 | $6.45 Million | $-7.92 Million | -1.228x | -97.47% |
| 2021-12-31 | $8.14 Million | $-5.06 Million | -0.622x | +79.36% |
| 2020-12-31 | $1.43 Million | $-4.31 Million | -3.012x | +99.10% |
| 2019-12-31 | $14.00K | $-4.70 Million | -335.429x | -262.14% |
| 2018-12-31 | $77.00K | $-7.13 Million | -92.623x | -16869.15% |
| 2017-12-31 | $8.39 Million | $-4.58 Million | -0.546x | +78.87% |
| 2016-12-31 | $572.71K | $-1.48 Million | -2.583x | -125.51% |
| 2015-12-31 | $1.15 Million | $-1.32 Million | -1.145x | -107.05% |
| 2014-12-31 | $-116.33K | $-1.89 Million | 16.243x | +689.94% |
| 2013-12-31 | $995.26K | $-2.74 Million | -2.753x | +72.88% |
| 2012-12-31 | $389.43K | $-3.95 Million | -10.152x | -690.49% |
| 2011-12-31 | $2.95 Million | $-3.78 Million | -1.284x | -73.45% |
| 2010-12-31 | $5.09 Million | $-3.77 Million | -0.740x | -118.68% |
| 2009-12-31 | $5.64 Million | $-1.91 Million | -0.339x | +21.07% |
| 2008-12-31 | $7.52 Million | $-3.22 Million | -0.429x | -27.13% |
| 2007-12-31 | $9.41 Million | $-3.18 Million | -0.337x | -61.31% |
| 2006-12-31 | $6.98 Million | $-1.46 Million | -0.209x | -- |
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more